Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronic myeloid leukemia TKI discontinuation study in the Brazilian public health system
RBR-6f5xbqPhase 2Not yet recruiting
- Sponsor
- Hemocentro Unicamp
- Start
- Aug 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib, nilotinib, dasatinib and bosutinib in chronic myelogenous leukemia (CML), sponsored by Hemocentro Unicamp. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on RBR-6f5xbq.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6f5xbq.